PTPRC Antibody

What is PTPRC and why is it important in immunological research?

PTPRC (CD45) is a transmembrane glycoprotein that functions as a protein tyrosine phosphatase receptor. It serves as an essential regulator of T and B cell antigen receptor-mediated activation pathways . The importance of PTPRC in immunological research stems from its critical role in controlling immune function through regulation of lymphocyte survival, cytokine responses, and T-cell receptor (TCR) signaling . Disruption of the equilibrium between protein tyrosine kinase and phosphatase activity involving CD45 can result in severe immunological disorders including immunodeficiency, autoimmunity, or malignancy .

For researchers, PTPRC antibodies serve as invaluable tools for investigating lymphocyte development, activation states, and functional responses. The protein's expression pattern makes it a useful marker for identifying and characterizing various immune cell populations, particularly during development and in disease states. Understanding CD45's structure, isoform expression, and functional mechanisms provides critical insights into fundamental immunological processes.

What are the different isoforms of PTPRC and how do they affect antibody selection?

The PTPRC gene can produce up to eight different isoforms through alternative splicing . These isoforms differ primarily in their extracellular domains, which affects their glycosylation patterns, molecular weights, and functional properties. The most well-characterized isoforms include CD45RA, CD45RB, CD45RC, and CD45RO, which are differentially expressed on various immune cell populations and at different stages of cell development and activation.

When selecting PTPRC antibodies for research, it is essential to consider which isoform(s) you aim to detect. Some antibodies recognize common epitopes present in all CD45 isoforms (pan-CD45), while others are specific for particular isoforms. For example, if studying naive versus memory T cells, researchers might select antibodies that distinguish between CD45RA (expressed on naive cells) and CD45RO (expressed on memory cells) . Review the antibody's datasheet carefully to confirm which epitope it recognizes and validate its specificity in your experimental system using appropriate positive and negative controls.

What are the optimal protocols for using PTPRC antibodies in flow cytometry?

For optimal flow cytometry results with PTPRC antibodies, researchers should consider several methodological factors:

• Sample preparation: Prepare single-cell suspensions from your tissue of interest using gentle dissociation methods to preserve cell surface antigens. Avoid excessive mechanical stress or enzymatic over-digestion that might damage the PTPRC epitopes.

• Antibody titration: Perform titration experiments to determine the optimal antibody concentration for your specific cell type and preparation. This minimizes background and ensures appropriate signal-to-noise ratios.

• Blocking step: Include a blocking step (typically with serum matching the secondary antibody host species) to reduce non-specific binding.

• Controls: Always include appropriate controls such as:

  • Unstained cells for autofluorescence assessment

  • Isotype controls matching the PTPRC antibody's isotype and concentration

  • Known positive and negative cell populations

• Compensation: When using multiple fluorochromes, proper compensation is essential to account for spectral overlap.

Given that PTPRC is expressed at high levels on most leukocytes, it can serve as an excellent marker for gating immune cell populations in complex samples . The selection of specific anti-PTPRC clones should be determined by your research question, particularly if you're investigating specific isoforms or if cross-reactivity with other species is a concern.

How should researchers validate the specificity of PTPRC antibodies?

Validating PTPRC antibody specificity is crucial for reliable research outcomes and should include multiple approaches:

• Western blotting: Confirm the antibody detects a protein of the expected molecular weight (approximately 147.5 kDa for the canonical form, though this varies by isoform) . Multiple bands may indicate detection of different isoforms or glycosylation states.

• Knockout/knockdown controls: Where possible, use PTPRC knockout or knockdown cell lines/tissues as negative controls.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide (if available) to demonstrate signal specificity.

• Cross-validation with multiple antibodies: Use antibodies targeting different epitopes of PTPRC to confirm consistent staining patterns.

• Flow cytometry validation: Compare staining patterns on known PTPRC-positive cells (e.g., lymphocytes) versus PTPRC-negative cells (e.g., mature erythrocytes) .

• Immunohistochemistry controls: Include appropriate tissue sections known to express or lack PTPRC as positive and negative controls, respectively.

Thorough validation not only ensures reliable results but also helps troubleshoot inconsistent findings that may arise from technical variations or biological differences in PTPRC expression across different cellular contexts.

How do PTPRC gene polymorphisms affect immune function, and what methodologies are best for their investigation?

PTPRC gene polymorphisms can significantly impact immune function and have been linked to various immune disorders. Two notable polymorphisms in humans are C77G and A138G . The C77G polymorphism affects the exon 4 splice silencer, leading to CD45RO isoform deficiency and has been associated with immune disorders including autoimmune hepatitis, HIV infection, and multiple sclerosis . The A138G mutation results in altered CD45 isoform expression with increased numbers of memory activated lymphocytes and enhanced interferon-gamma production .

For investigating these polymorphisms, researchers should consider the following methodological approaches:

• Genotyping techniques: PCR-RFLP (Restriction Fragment Length Polymorphism), allele-specific PCR, or next-generation sequencing for accurate identification of specific polymorphisms.

• Functional assays: Measure T and B cell proliferation, cytokine production, and receptor signaling to assess the functional impact of polymorphisms.

• Flow cytometry analysis: Quantify CD45 isoform expression patterns on different immune cell subpopulations to correlate with genotypic variations.

• Cell signaling studies: Investigate phosphorylation states of downstream signaling molecules (particularly Src family kinases) affected by altered PTPRC activity.

• Clinical correlation: For translational studies, correlate polymorphism data with clinical phenotypes, disease progression, or treatment responses in patient cohorts.

When designing such studies, it's crucial to consider the ethnic background of your study population, as the frequency and impact of these polymorphisms can vary significantly between different ethnic groups.

What are the current methodological approaches for investigating PTPRC in severe combined immunodeficiency (SCID)?

PTPRC mutations can lead to severe combined immunodeficiency (SCID), particularly types 104 and 105 . Investigating PTPRC in SCID contexts requires a comprehensive approach combining genetic, molecular, cellular, and functional methodologies:

• Genetic screening: Next-generation sequencing techniques to identify novel or known mutations in the PTPRC gene. This should include both coding regions and potential regulatory elements affecting expression.

• Protein expression analysis: Western blotting and flow cytometry to quantify PTPRC protein levels and assess isoform distribution patterns in patient samples compared to healthy controls.

• Phosphatase activity assays: Biochemical assays to measure the enzymatic activity of PTPRC and determine if mutations result in loss or alteration of phosphatase function.

• Immune cell functional studies: Comprehensive assessment of T and B cell development, proliferation capacity, and antigen receptor signaling in patient-derived cells.

• Signaling pathway analysis: Phospho-flow cytometry or western blotting to examine the phosphorylation status of downstream targets in the TCR signaling pathway, particularly focusing on Lck and Fyn kinases.

• Mouse models: Generation of knockin mice harboring patient-specific mutations to recapitulate the disease phenotype and test potential therapeutic interventions.

• iPSC-derived immune cells: Patient-specific induced pluripotent stem cells differentiated into hematopoietic lineages to study developmental defects caused by PTPRC mutations.

These approaches can provide valuable insights into how specific PTPRC mutations impair immune cell development and function, potentially leading to novel therapeutic strategies for SCID patients .

How can researchers effectively use PTPRC antibodies in multiplex immunoassays?

Integrating PTPRC antibodies into multiplex immunoassays requires careful consideration of several technical factors:

• Antibody compatibility: Select PTPRC antibodies with minimal cross-reactivity to other targets in your panel. Monoclonal antibodies like those available from commercial sources may offer higher specificity .

• Panel design: When designing a multiplex panel:

  • Choose fluorochromes for PTPRC based on its expected expression level (bright fluorochromes for low-expressed targets, dimmer ones for highly expressed targets like PTPRC)

  • Account for potential spectral overlap between fluorochromes

  • Consider the cellular localization of targets (membrane for PTPRC)

• Optimization strategies:

  • Perform antibody titrations individually before combining in a multiplex panel

  • Test different fixation and permeabilization protocols to ensure compatibility with all antibodies

  • Evaluate potential epitope masking or steric hindrance between antibodies

• Validation approaches:

  • Compare results from single-stained samples with multiplex results

  • Include fluorescence-minus-one (FMO) controls to accurately set gates

  • Use known reference samples to validate expected staining patterns

• Data analysis considerations:

  • Implement appropriate compensation matrices

  • Consider dimensionality reduction techniques (t-SNE, UMAP) for high-parameter data

  • Validate findings using alternate methodologies

The high expression level of PTPRC on most immune cells makes it an excellent marker for identifying leukocyte populations in complex samples, serving as an anchor marker in many immunophenotyping panels .

What are the challenges and solutions in investigating interactions between PTPRC and its ligands?

Studying interactions between PTPRC and its ligands presents several methodological challenges:

• Challenge: PTPRC has multiple potential ligands, including PP14/PAEP, galectin-1, CD22, and viral proteins like pUL11 , making comprehensive interaction studies complex.
  Solution: Employ systematic approaches including proximity ligation assays, co-immunoprecipitation with multiple antibodies targeting different PTPRC domains, and FRET/BRET technologies to validate interactions in physiological contexts.

• Challenge: PTPRC interactions may be transient or of low affinity.
  Solution: Use chemical crosslinking combined with mass spectrometry to capture and identify transient interactions. Surface plasmon resonance or bio-layer interferometry can quantify binding kinetics and affinities.

• Challenge: PTPRC has extensive glycosylation that may modulate ligand binding .
  Solution: Compare binding studies with differentially glycosylated forms of PTPRC, using enzymatic deglycosylation or expression systems with altered glycosylation capacity.

• Challenge: The large extracellular domain of PTPRC makes structural studies difficult.
  Solution: Focus on domain-specific interactions using recombinant protein fragments representing specific PTPRC domains.

• Challenge: Functional consequences of ligand binding are context-dependent.
  Solution: Develop cell-type specific assays measuring downstream signaling events (e.g., LCK phosphorylation status), calcium flux, or functional outcomes like proliferation or cytokine production in response to specific ligand engagement.

For example, when studying the interaction between PTPRC and viral protein pUL11, researchers should note that different concentrations of pUL11 can lead to varying effects on the phosphorylation of LCK at different residues, highlighting the complex nature of these interactions .

How should researchers interpret PTPRC antibody data in the context of innate immune cell research?

While PTPRC is traditionally associated with adaptive immunity, recent evidence indicates it plays essential roles in the innate immune system . When using PTPRC antibodies in innate immune cell research, consider these interpretative frameworks:

• Cell type-specific expression patterns:

  • PTPRC can be used as a marker to identify specific macrophage populations, including alveolar macrophages and interstitial macrophages

  • Different innate immune cell subtypes may express distinct PTPRC isoforms or levels

  • Compare expression patterns across multiple markers to accurately identify cell populations

• Functional context interpretation:

  • Correlate PTPRC expression with functional readouts (cytokine production, phagocytic capacity)

  • Consider activation state—PTPRC phosphatase activity may regulate innate immune signaling differently depending on cellular activation

  • Integrate with signaling pathway analyses, particularly those involving tyrosine phosphorylation cascades

• Technical considerations:

  • Use multiple antibody clones recognizing different epitopes to validate findings

  • Account for potential differences in PTPRC accessibility or conformation in different innate immune cell types

  • Consider tissue-specific factors that may affect antibody binding or PTPRC function

• Comparative analysis approaches:

  • Compare findings across species, considering potential differences in PTPRC structure and function

  • Validate flow cytometry findings with imaging techniques to confirm cellular localization

  • Correlate PTPRC expression with other innate immune markers to establish reliable identification panels

When designing studies focusing on PTPRC in innate immunity, researchers should particularly focus on macrophage populations, where PTPRC may serve as a useful marker for identifying specific subpopulations or activation states .

What controls are essential when using PTPRC antibodies in experimental workflows?

Robust experimental design with appropriate controls is critical when working with PTPRC antibodies. Essential controls include:

• Positive and negative tissue/cell controls:

  • Positive: Lymphoid tissues (lymph nodes, spleen) known to express high levels of PTPRC

  • Negative: Mature erythrocytes or non-hematopoietic cell lines that lack PTPRC expression

• Antibody-specific controls:

  • Isotype controls matched to the primary antibody's isotype, species, and concentration

  • Secondary antibody-only controls (for indirect detection methods)

  • Blocking peptide controls where the primary antibody is pre-incubated with excess immunizing peptide

• Technical controls:

  • Unstained samples to establish baseline autofluorescence in flow cytometry

  • Fluorescence-minus-one (FMO) controls for multicolor flow panels

  • Single-stained compensation controls for each fluorochrome

• Biological validation controls:

  • Comparison of staining patterns across known biological states (e.g., naive vs. activated lymphocytes)

  • Correlation with functional readouts relevant to the research question

• Method-specific controls:

  • For immunoprecipitation: Pre-immune serum or IgG controls

  • For Western blotting: Molecular weight markers and loading controls

  • For immunohistochemistry: Absorption controls and secondary antibody controls

Including these controls allows for accurate interpretation of results and troubleshooting of unexpected outcomes, particularly important given the various isoforms and extensive post-translational modifications of PTPRC .

How can researchers address common technical challenges with PTPRC antibodies?

Researchers commonly encounter several technical challenges when working with PTPRC antibodies. Here are methodological solutions for addressing them:

• Challenge: Variable staining intensity across sample types
  Solution: Optimize fixation conditions specifically for your tissue/cell type. For formalin-fixed tissues, test different antigen retrieval methods (heat-induced vs. enzymatic). For flow cytometry, compare different fixation buffers and incubation times.

• Challenge: Cross-reactivity with other proteins
  Solution: Validate antibody specificity using multiple techniques (Western blot, immunoprecipitation, flow cytometry). Consider using recombinant monoclonal antibodies like CPTC-PTPRC-2 for improved specificity .

• Challenge: Distinguishing between PTPRC isoforms
  Solution: Select antibodies targeting isoform-specific epitopes. Complement antibody-based detection with molecular techniques like RT-PCR to confirm isoform expression patterns.

• Challenge: Poor signal in immunohistochemistry
  Solution: Test different antibody concentrations and incubation conditions. Consider amplification systems like tyramide signal amplification if the target expression is low.

• Challenge: Inconsistent results between different antibody clones
  Solution: Compare antibodies targeting different epitopes of PTPRC. Different epitopes may be differentially accessible depending on protein conformation, fixation method, or cellular context.

• Challenge: Interference from heavy glycosylation
  Solution: For biochemical studies, consider using enzymatic deglycosylation to improve epitope accessibility. In flow cytometry, longer incubation times or different detergents in staining buffers may improve staining.

• Challenge: Non-specific background in immunofluorescence
  Solution: Implement more stringent blocking procedures using a combination of serum, BSA, and commercial blocking reagents. Include additional washing steps with detergents like Tween-20 or Triton X-100.

Addressing these challenges systematically will improve data quality and reproducibility in PTPRC-focused research.

What emerging methodologies are advancing PTPRC research?

Several cutting-edge methodologies are expanding our understanding of PTPRC biology and offering new research opportunities:

• Single-cell technologies: Single-cell RNA sequencing and CyTOF (mass cytometry) are enabling researchers to precisely characterize PTPRC isoform expression patterns and correlate them with cellular identity and function at unprecedented resolution.

• CRISPR-Cas9 gene editing: Targeted modification of PTPRC can create model systems to study specific polymorphisms or mutations associated with immunodeficiency . This approach allows for precise dissection of structure-function relationships.

• Spatial transcriptomics and proteomics: These techniques allow researchers to map PTPRC expression in intact tissues, providing crucial spatial context for understanding its function in different microenvironments.

• Proximity labeling methods: BioID or APEX2-based approaches can identify novel PTPRC-interacting proteins in living cells, expanding our understanding of its signaling networks.

• Advanced imaging techniques: Super-resolution microscopy and live-cell imaging are providing new insights into PTPRC dynamics during immune cell activation and signaling.

• Protein structure analysis: Cryo-electron microscopy is advancing our understanding of PTPRC's complex structure, particularly its heavily glycosylated extracellular domains.

• Systems biology approaches: Integration of multi-omics data is helping researchers understand how PTPRC functions within broader signaling networks and how perturbations affect immune system homeostasis.

These emerging methodologies are particularly valuable for investigating PTPRC's role in the innate immune system, which remains less well characterized than its functions in adaptive immunity .

How might PTPRC research inform therapeutic strategies for immunological disorders?

PTPRC research has significant implications for developing therapeutic strategies for various immunological disorders:

• Immunodeficiency disorders: Understanding the molecular mechanisms underlying PTPRC-associated severe combined immunodeficiency (SCID types 104 and 105) could inform targeted gene therapy approaches or the development of recombinant proteins to restore immune function.

• Autoimmune diseases: Given PTPRC's role in regulating T cell activation and the association of certain polymorphisms with autoimmune conditions , modulating CD45 activity could represent a therapeutic strategy. Research into the A138G polymorphism, which affects interferon-gamma production , may inform treatments for conditions characterized by dysregulated cytokine responses.

• Cancer immunotherapy: PTPRC's role in immune cell activation makes it relevant for cancer immunotherapy research. Understanding how PTPRC regulates immune checkpoint pathways could identify new targets or combination strategies to enhance anti-tumor immune responses.

• Transplantation medicine: PTPRC research may inform strategies to modulate immune responses in transplantation settings, potentially through targeted antibodies or small molecules that modify CD45 phosphatase activity.

• Infectious disease: The interaction between viral proteins like pUL11 and PTPRC highlights potential viral evasion mechanisms. Understanding these interactions could lead to novel anti-viral strategies targeting host-pathogen interfaces.

Future therapeutic approaches may include developing small molecule modulators of PTPRC phosphatase activity, antibodies targeting specific isoforms, or gene editing strategies to correct pathogenic mutations in severe immunodeficiencies.